newsfilter
← Latest News
GlobeNewswire·

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidates in Acumen's